Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AREnA: Enzalutamide plus targeted radiotherapy in nonmetastatic castration-resistant prostate cancer
jRCTs031210290Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoint: PSA-progression free survival. Started Oct 2021; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031210290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210290.